Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
BIONTECH SE (BNTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$85.86-5.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BNTX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain operating margins through effective cost management | A supporting condition in BIONTECH SE's published investment case. The stated target is >=20% operating margin by FY27. | Intact | operating margin falls below 20% by FY27 | Operating margin: -897.82% FY2026-Q2; GAAP. Published target: >=20% operating margin by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 4, 2026-897.82197 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
The evidence does not support a clear label such as a durable compounder or a turnaround. The current long-term thesis is insufficiently established because recent financial-performance history is limited, and overall confidence is low.
The snapshot provides no valuation level or market expectations, so it is not possible to describe whether BNTX looks cheap, fair, or expensive versus peers. No pricing-fragility signals were found, but that does not establish what expectations are already reflected.
Near term, the risk of an earnings miss is elevated, given consecutive misses and a high-miss-rate industry. The Healthcare sector backdrop has strengthened, but the evidence does not show a company-specific operating trend or management execution record to support a clearer multi-year outlook.
The near-term setup hinges on whether BNTX breaks its run of earnings misses. Over the broader view, a stronger Healthcare backdrop could help, while weaker sector bellwether results or further job-market deterioration could remove that support.
For the next 1 to 3 years, the long-term thesis remains unclear: sector conditions are more supportive, but company-level evidence is thin and near-term earnings risk is elevated. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Advancement of oncology vaccine candidates in clinical trials |
| BioNTech has strong potential in oncology with several promising vaccine candidates. |
| Improving |
| fewer than 2 candidates reach Phase 3 trials by FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve revenue growth from new product launches | A primary condition in BIONTECH SE's published investment case. The stated target is >=15% YoY revenue growth by FY27. | Intact | revenue growth falls below 15% YoY by FY27 | Revenue growth: -59.51% FY2026-Q2; GAAP. Published target: >=15% YoY revenue growth by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 4, 2026-59.509202 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.33 → $-5.23 · observed estimates
$2.23B → $1.85B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.33 | $2,230,748,290 | 7 / 17 |
| 2026-07-25 | $-4.72 | $2,216,160,072 | 8 / 12 |
| 2026-07-26 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-07-27 | $-4.70 | $2,209,284,446 | 8 / 12 |
| 2026-07-28 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-07-29 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-07-30 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-07-31 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-08-01 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-08-02 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-08-03 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-08-04 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-08-05 | $-4.40 | $2,139,864,780 | 7 / 17 |
| 2026-08-06 | $-4.33 | $2,230,776,480 | 7 / 17 |
| 2026-08-07 | $-5.73 | $1,906,614,528 | 8 / 12 |
| 2026-08-08 | $-4.88 | $1,879,941,370 | 9 / 17 |
| 2026-08-09 | $-4.88 | $1,879,941,370 | 9 / 17 |
| 2026-08-10 | $-4.88 | $1,879,941,370 | 9 / 17 |
| 2026-08-11 | $-5.73 | $1,906,614,528 | 8 / 12 |
| 2026-08-12 | $-4.86 | $1,864,227,900 | 9 / 17 |
| 2026-08-13 | $-4.86 | $1,864,227,900 | 9 / 17 |
| 2026-08-14 | $-5.73 | $1,906,614,528 | 8 / 12 |
| 2026-08-15 | $-5.73 | $1,906,614,528 | 9 / 12 |
| 2026-08-16 | $-5.73 | $1,906,614,528 | 9 / 12 |
| 2026-08-17 | $-5.73 | $1,906,614,528 | 9 / 12 |
| 2026-08-18 | $-5.73 | $1,906,614,528 | 9 / 12 |
| 2026-08-19 | $-5.73 | $1,906,614,528 | 9 / 12 |
| 2026-08-20 | $-5.68 | $1,891,987,143 | 9 / 12 |
| 2026-08-21 | $-5.68 | $1,892,181,580 | 9 / 12 |
| 2026-08-22 | $-5.68 | $1,892,181,580 | 9 / 12 |
| 2026-08-23 | $-5.68 | $1,892,181,580 | 9 / 12 |
| 2026-08-24 | $-5.68 | $1,892,181,580 | 9 / 12 |
| 2026-08-25 | $-5.68 | $1,892,197,783 | 9 / 12 |
| 2026-08-26 | $-5.66 | $1,860,318,227 | 9 / 12 |
| 2026-08-27 | $-5.66 | $1,860,318,227 | 9 / 12 |
| 2026-08-28 | $-5.66 | $1,860,318,227 | 9 / 12 |
| 2026-08-29 | $-5.65 | $1,858,659,323 | 9 / 12 |
| 2026-08-30 | $-5.65 | $1,858,671,463 | 9 / 12 |
| 2026-08-31 | $-5.65 | $1,858,671,463 | 9 / 12 |
| 2026-09-01 | $-5.64 | $1,853,279,987 | 9 / 12 |
| 2026-09-02 | $-5.62 | $1,849,036,991 | 9 / 12 |
| 2026-09-03 | $-5.62 | $1,848,382,996 | 9 / 12 |
| 2026-09-04 | $-5.64 | $1,854,300,858 | 9 / 12 |
| 2026-09-05 | $-5.64 | $1,854,300,858 | 9 / 12 |
| 2026-09-06 | $-5.64 | $1,854,300,858 | 9 / 12 |
| 2026-09-07 | $-5.64 | $1,854,300,858 | 9 / 12 |
| 2026-09-08 | $-5.63 | $1,852,434,578 | 9 / 12 |
| 2026-09-09 | $-5.74 | $1,811,552,635 | 8 / 12 |
| 2026-09-10 | $-5.74 | $1,811,926,726 | 9 / 12 |
| 2026-09-11 | $-5.75 | $1,813,703,660 | 9 / 12 |
| 2026-09-12 | $-5.73 | $1,809,448,372 | 9 / 12 |
| 2026-09-13 | $-5.73 | $1,809,448,372 | 9 / 12 |
| 2026-09-14 | $-5.73 | $1,809,448,372 | 9 / 12 |
| 2026-09-15 | $-5.73 | $1,807,484,392 | 9 / 12 |
| 2026-09-16 | $-5.70 | $1,800,015,882 | 9 / 12 |
| 2026-09-17 | $-5.71 | $1,797,014,012 | 9 / 12 |
| 2026-09-18 | $-5.71 | $1,797,014,012 | 9 / 12 |
| 2026-09-19 | $-5.71 | $1,797,014,012 | 9 / 12 |
| 2026-09-20 | $-5.68 | $1,787,342,766 | 9 / 12 |
| 2026-09-21 | $-5.65 | $1,779,807,483 | 9 / 12 |
| 2026-09-22 | $-5.66 | $1,781,780,271 | 9 / 12 |
| 2026-09-23 | $-5.66 | $1,782,470,975 | 9 / 12 |
| 2026-09-24 | $-5.66 | $1,782,470,975 | 9 / 12 |
| 2026-09-25 | $-5.64 | $1,774,422,794 | 9 / 12 |
| 2026-09-26 | $-5.64 | $1,774,868,557 | 9 / 12 |
| 2026-09-27 | $-5.64 | $1,774,868,557 | 9 / 12 |
| 2026-09-28 | $-5.65 | $1,780,420,340 | 9 / 12 |
| 2026-09-29 | $-5.67 | $1,784,592,185 | 9 / 12 |
| 2026-09-30 | $-5.67 | $1,784,592,185 | 9 / 12 |
| 2026-10-01 | $-5.66 | $1,782,612,014 | 9 / 12 |
| 2026-10-02 | $-5.67 | $1,784,716,018 | 9 / 12 |
| 2026-10-03 | $-5.62 | $1,769,687,889 | 9 / 12 |
| 2026-10-04 | $-5.62 | $1,771,082,364 | 9 / 12 |
| 2026-10-05 | $-5.63 | $1,773,417,608 | 9 / 12 |
| 2026-10-06 | $-5.64 | $1,775,326,952 | 9 / 12 |
| 2026-10-07 | $-5.62 | $1,770,214,328 | 9 / 12 |
| 2026-10-08 | $-5.64 | $1,775,955,827 | 9 / 12 |
| 2026-10-09 | $-5.54 | $1,766,207,276 | 9 / 12 |
| 2026-10-10 | $-5.54 | $1,766,207,276 | 9 / 12 |
| 2026-10-11 | $-5.52 | $1,770,108,512 | 9 / 12 |
| 2026-10-12 | $-5.53 | $1,772,819,000 | 9 / 12 |
| 2026-10-13 | $-5.56 | $1,776,236,976 | 9 / 12 |
| 2026-10-14 | $-5.55 | $1,773,584,323 | 9 / 12 |
| 2026-10-15 | $-5.58 | $1,781,700,286 | 9 / 12 |
| 2026-10-16 | $-5.64 | $1,783,723,687 | 9 / 12 |
| 2026-10-17 | $-5.64 | $1,783,723,687 | 9 / 12 |
| 2026-10-18 | $-5.64 | $1,783,958,898 | 9 / 12 |
| 2026-10-19 | $-5.65 | $1,786,518,608 | 9 / 12 |
| 2026-10-20 | $-5.65 | $1,786,518,608 | 9 / 12 |
| 2026-10-21 | $-5.55 | $1,795,885,790 | 9 / 12 |
| 2026-10-22 | $-5.55 | $1,795,134,640 | 9 / 12 |
| 2026-10-23 | $-5.55 | $1,792,673,428 | 9 / 12 |
| 2026-10-24 | $-5.55 | $1,792,673,428 | 9 / 12 |
| 2026-10-25 | $-5.55 | $1,792,673,428 | 9 / 12 |
| 2026-10-26 | $-5.54 | $1,790,132,307 | 9 / 12 |
| 2026-10-27 | $-5.54 | $1,790,132,307 | 9 / 12 |
| 2026-10-28 | $-5.53 | $1,785,815,716 | 9 / 12 |
| 2026-10-29 | $-5.51 | $1,778,400,122 | 9 / 12 |
| 2026-10-30 | $-5.52 | $1,782,699,248 | 9 / 12 |
| 2026-10-31 | $-5.53 | $1,786,151,335 | 9 / 12 |
| 2026-11-01 | $-5.53 | $1,786,151,335 | 9 / 12 |
| 2026-11-02 | $-5.53 | $1,786,151,335 | 9 / 12 |
| 2026-11-03 | $-5.54 | $1,787,701,578 | 9 / 12 |
| 2026-11-04 | $-5.23 | $1,850,961,078 | 9 / 12 |
| 2026-11-05 | $-5.23 | $1,850,961,078 | 9 / 12 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 14 Buy / Strong Buy · 7 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 6 recorded
0 raises · 2 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.